The current way to produce antivenoms is antiquated. Experiments in mice suggest that an artificial intelligence approach could save time and money.

During transcription, newly minted RNA sticks to its DNA template, forming a 3-stranded structure known as an R-loop. While ...

Given the long-term tailwinds of biologics, the demand for high quality containers − such as pre-filled syringes and ...

CREAL's next-generation light field display developed for Augmented Reality (AR) glasses is now ready for integration. By replicating real-world light to deliver genuine focus depth, the display ...

Each year, snake bites kill upwards of 100,000 people and permanently disable hundreds of thousands more, according to ...

AI optimizes existing knowledge but doesn't expedite drug approval or reduce costs compared to traditional methods. Explore ...

Iluzanebart is under clinical development by Vigil Neuroscience and currently in Phase I for Unspecified Neurologic Disorders.

MRT-6160 is under clinical development by Monte Rosa Therapeutics and currently in Phase I for Rheumatoid Arthritis.

Duke neuroscientist Kafui Dzirasa wants nothing less than to reengineer the brain’s electrical patterns to treat anxiety, ...

This dynamic field has seen tremendous change in recent years. Leaders share their perspectives on what trends we can expect in 2025.

SORL1 dysfunction messes with endosomes in neurons, and with lysosomes in microglia.